This phase 1 trial evaluates the safety and efficacy of the triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with B-cell malignancies.

Researchers are evaluating ibrutinib with prednisone as a potential treatment option for patients with newly diagnosed moderate or severe chronic graft-versus-host disease (cGVHD).

This 4-year follow-up of the phase 3 RESONATE study provides updated data on the efficacy and safety of ibrutinib, comparing the long-term efficacy and safety of ibrutinib versus ofatumumab in patients with chronic lymphocytic leukemia (CLL).

GENUINE, the first randomized phase 3 trial conducted to assess the addition of a novel agent, ublituximab, to ibrutinib in high-risk, relapsed/refractory chronic lymphocytic leukemia (CLL), evaluates ibrutinib monotherapy versus ublituximab and ibrutinib.

CALGB 10404, a randomized phase 2 study, compares different fludarabine chemoimmunotherapy regimens in patients with non-del(11q) chronic lymphocytic leukemia (CLL).

This retrospective cohort study examines the use and efficacy of ibrutinib in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter transformation.